On Friday, Tandem Diabetes Care Inc (TNDM) stock saw a decline, ending the day at $30.6 which represents a decrease of $-2.72 or -8.16% from the prior close of $33.32. The stock opened at $33.71 and ...

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) were down 9.6% on Friday after Canaccord Genuity Group lowered their price target on the stock from $57.00 to $56.00. Canaccord ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. We are living in exciting ...

In a report released today, Patrick Wood from Morgan Stanley maintained a Buy rating on Insulet (PODD – Research Report), with a price ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

During quarterly earnings calls across the medtech industry, a recurring question has been on investors’ minds: If ...

Q3 2024 Earnings Call Transcript November 6, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0 ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Equities research analysts at Sanford C. Bernstein began coverage on shares of Tandem Diabetes Care (NASDAQ:TNDM – Get Free ...

Diabetes costs US employers over $106B in lost productivity. Learn how data-driven support can improve employee health and ...

Discover the latest findings from the CDC on the growing prevalence of adult diabetes in the US, including key factors such as age, weight and education levels.

Bernstein has recently initiated Tandem Diabetes Care Inc (TNDM) stock to Outperform rating, as announced on Today, according to Finviz. Earlier, on October 4, 2024, Goldman had initiated the stock to ...